Global Intellectual Property Specialists

Strategic global thinking for the pharmaceutical and biopharmaceutical industries

Our Capabilities

We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.

Explore our BioBlast®

View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date.

Our People

Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.

Award-winning IP services

Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.

PEARCE IP

Our Capabilities

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.

We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.

Patent: Legal and Attorney Services

Trade Mark: Legal and Attorney Services

Commercial IP Services

Regulatory Affairs Services

View our Capabilities

IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS

Our Leaders

Naomi Pearce

Executive Lawyer, Patent Attorney & Trade Mark Attorney

CEO

Katrina Crooks

Executive Lawyer and Patent Attorney

Head of Litigation

Jacinta Flattery O’Brien PhD

Special Counsel, Patent Attorney

Grant Shoebridge PhD

Special Counsel, Patent Attorney

Kate Legge

Special Counsel, Lawyer

PEARCE IP BLOG

Read our latest updates & insights

Jayne Jagot appointed to Australia’s High Court bench – a new era for diversity and for patent law

Jayne Jagot appointed to Australia’s High Court bench – a new era for diversity and for patent law

Jayne Jagot appointed to Australia’s High Court bench – a new era for diversity and for patent law

by Naomi Pearce, Kate Legge | Sep 30, 2022

The Australian High Court will have an experienced intellectual property judge on its bench, with the appointment of...

BioBlast® w/e 23 Sep 22: Stada/Alvotech’s adalimumab launch, AZ/Merck olaparib PRC approval, AVEO’s ficlatuzumab US fast-tracked, Sandoz’s denosumab, interchangeability in the EU, Coherus’ US ranibizumab launch, Celltrion invalidates Rituxan® patent, Formycon’s pembrolizumab, Celltrion’s bevacizumab

BioBlast® w/e 23 Sep 22: Stada/Alvotech’s adalimumab launch, AZ/Merck olaparib PRC approval, AVEO’s ficlatuzumab US fast-tracked, Sandoz’s denosumab, interchangeability in the EU, Coherus’ US ranibizumab launch, Celltrion invalidates Rituxan® patent, Formycon’s pembrolizumab, Celltrion’s bevacizumab

BioBlast® w/e 23 Sep 22: Stada/Alvotech’s adalimumab launch, AZ/Merck olaparib PRC approval, AVEO’s ficlatuzumab US fast-tracked, Sandoz’s denosumab, interchangeability in the EU, Coherus’ US ranibizumab launch, Celltrion invalidates Rituxan® patent, Formycon’s pembrolizumab, Celltrion’s bevacizumab

by Naomi Pearce, Emily Dwyer | Sep 26, 2022

Significant biosimilar activities this week include: 22 Sep 22 | CH | STADA launches Alvotech’s Hukyndra® (100mg/mL...

Read all News Stories

Explore our BioBlast®

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

infliximab | Remicade® | Johnson & Johnson

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

rituximab | Rituxan®/MabThera® | Genentech/Biogen

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson

View latest BioBlast® updates

See all Bioblast Updates

OUR VISION

By 2027, be the premier life sciences IP practice in Australia.

Contact Our Team

AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS

Awards